Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study

Thrombosis Research

Volumn 118, Issue 4, 2006, Pages 487-493

  Gianetti, Jacopo ^a   Parri, Maria Serena ^a   Sbrana, Silverio ^a   Paoli, Fabrizio ^a   Maffei, Stefano ^a   Paradossi, Umberto ^a   Berti, Sergio ^a   Clerico, Aldo ^a   Biagini, Andrea ^a  

^a G PASQUINUCCI HOSPITAL   (Italy)

Author keywords

PCI; PFA 100; Platelet activation

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE DONOR; PROSTAGLANDIN SYNTHASE; TICLOPIDINE; TIROFIBAN; WARFARIN;

ACUTE CORONARY SYNDROME; ARTICLE; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; ENZYME INHIBITION; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; STABLE ANGINA PECTORIS; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COLLAGEN; CORONARY ARTERY DISEASE; EPINEPHRINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 33747887205     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.10.011     Document Type: Article

References (31)

1. Mehta S.R., and Yusuf S. Short and long-term oral antiplatelet therapy in acute coronary syndromes and PCI. J Am Coll Cardiol 41 (2003) 79S-88S
2. Jilma B. Therapeutic failure and resistance to aspirin. J Am Coll Cardiol 41 (2003) 961-965
3. Wong S, Appleberg M, Ward CM, Lewis DR. Aspirin resistance in cardiovascular disease: a review. Eur J Vasc Endovasc Surg 27: 456-65.
4. Howard P.A. Aspirin resistance. Ann Pharmacother 36 (2002) 1620-1624
5. Christiaens L., Macchi L., Herpin D., Coisne D., Duplantier C., Allal J., et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 108 (2003) 115-119
6. Frossard M., Fuchs I., Leitner J.M., et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110 (2004) 1392-1397
7. Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S., et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST elevation myocardial infarction 2002: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 106 (2002) 1893-1900
8. Homoncik M., Jilma B., Hergovich N., Stohlawetz P., Panzer S., and Speiser W. Monitoring of aspirin pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83 (2000) 316-321
9. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 138 (2001) 152-163
10. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
11. Grau A.J., Reiners S., Lichy C., Buggle F., and Ruf A. Platelet function under aspirin, clopidogrel and both after ischemic stroke: a case-crossover study. Stroke 34 (2003) 849-854
12. Jilma B. Synergistic effect of clopidogrel and aspirin detected with the PFA-100 in stroke patients. Stroke 34 (2003) 854
13. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
14. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 138 (2001) 152-163
15. Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., et al. Resistance to aspirin in vitro is associated with increased platelet activity to adenosine diphosphate. Thromb Res 107 (2002) 45-49
16. Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24 (2004) 1-8
17. Eikelboom J.W., and Hankey G.J. Aspirin resistance: a new independent predictor of vascular events?. J Am Coll Cardiol 41 (2003) 966-968
18. Trip M.D., Cats V.M., van Capelle F.J., and Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322 (1990) 1549-1554
19. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
20. Kabbani S.S., Watkins M.W., Ashikaga T., Terrien E.F., Holoch P.A., Sobel B.E., et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 104 (2001) 81-86
21. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
22. Gum P.A., Kottke-Merchant K., Welsh P., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
23. Gurbel P.A., Samara W.M., and Bliden K.P. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets 15 (2004) 95-99
24. Chandrasekar B., and Tanguay J.F. Platelets and restenosis. J Am Coll Cardiol 35 (2000) 555-562
25. Uchida K., Sasahara M., Morigami N., Hazama F., and Kinoshita M. Expression of platelet-derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Atherosclerosis 124 (1996) 9-23
26. Myllarniemi M., Calderon L., Lemstrom K., Buchdunger E., and Hayry P. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J 11 (1997) 1119-1126
27. Jaremo P., Lindahl T.L., Fransson S.G., and Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Int Med 252 (2002) 233-238
28. Gurbel P.A., Bliden K.P., Bonnie L.H., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
29. Kabbani S.S., Watkins M.W., Ashikaga T., Terrien E.F., Sobel B.E., and Schneider D. Platelet reactivity characterized prospectively: a determination of outcome 90 days after percutaneous coronary intervention. Circulation 104 (2001) 181-186
30. Chakroun T., Gerotziafas G., Robert F., Lecrubier C., Samama M.M., Hatmi M., et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Brit J Haem 124 (2004) 80-85
31. Kereiakes D.J., Lorenz T., Young J.J., Kukielka G., Mueller M.N., Nanniazz-Alaimo L., et al. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis 12 (2001) 123-127